Raia Drogasil SA
BOVESPA:RADL3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Raia Drogasil SA
Revenue
Raia Drogasil SA
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Raia Drogasil SA
BOVESPA:RADL3
|
Revenue
R$44.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
17%
|
CAGR 10-Years
17%
|
|
|
Empreendimentos Pague Menos SA
BOVESPA:PGMN3
|
Revenue
R$14.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Dimed SA Distribuidora de Medicamentos
BOVESPA:PNVL3
|
Revenue
R$5.5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
d
|
d1000 Varejo Farma Participacoes SA
BOVESPA:DMVF3
|
Revenue
R$2.7B
|
CAGR 3-Years
22%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
Raia Drogasil SA
Glance View
Raia Drogasil SA, Brazil's pharmaceutical titan, stands as a testament to the transformative power of strategic mergers and innovative retail management. Born out of the merger of Drogasil and Droga Raia, two of Brazil's enduring pharmacy chains, the company today operates an extensive network of retail stores across the nation. This strategic merger in 2011 was not merely a consolidation of operations but a fusion of distinct corporate cultures and expertise, aimed at enhancing operational efficiencies and expanding market share. By leveraging economies of scale, Raia Drogasil has entrenched itself as a formidable force in Brazil's healthcare retail sector, boasting a strong presence in both high-density urban centers and emerging markets in Brazil. The company's business model is built on a robust mix of health and wellness products, encompassing everything from prescription medications to over-the-counter remedies and personal care items. Raia Drogasil has adeptly positioned itself to capitalize on Brazil's growing healthcare demands, thanks to its comprehensive product offerings and strategic store locations. Each store functions as both a destination for health-conscious consumers and a vital link in the greater logistical chain that ensures timely product availability. By intertwining brick-and-mortar retail with digital innovation, Raia Drogasil not only drives revenue through traditional sales channels but also through its dynamic e-commerce platform. This synergy allows the company to tap into the evolving preferences of tech-savvy consumers, thereby making Raia Drogasil a leader in seamlessly integrating shopping experiences that cater to modern customer expectations.
See Also
What is Raia Drogasil SA's Revenue?
Revenue
44.3B
BRL
Based on the financial report for Dec 31, 2025, Raia Drogasil SA's Revenue amounts to 44.3B BRL.
What is Raia Drogasil SA's Revenue growth rate?
Revenue CAGR 10Y
17%
Over the last year, the Revenue growth was 14%. The average annual Revenue growth rates for Raia Drogasil SA have been 15% over the past three years , 17% over the past five years , and 17% over the past ten years .